✦ LIBER ✦

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

✍ Scribed by Schernthaner, G.; Barnett, A. H.; Patel, S.; Hehnke, U.; von Eynatten, M.; Woerle, H.-J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Linagliptin , a dipeptidyl peptidase-4 i

✍ Forst, Thomas; Pfützner, Andreas 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 257 KB

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Long-term safety, tolerability, and effi

✍ Masato Odawara; Takashi Kadowaki; Naoko Tajima; Mikio Nishii; Tadaaki Taniguchi; 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 377 KB

Efficacy, safety and dose-response relat

✍ Kadowaki, T.; Kondo, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

Efficacy and safety of the dipeptidyl pe

✍ R. E. Pratley; M. S. Kipnes; P. R. Fleck; C. Wilson; Q. Mekki; Alogliptin Study 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

The efficacy and safety of the dipeptidy

✍ Robert Frederich, Robert McNeill, Niklas Berglind, Douglas Fleming, Roland Chen 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 239 KB